Figure 3. Adjusted Associations Between P2Y₁₂ Inhibitor Copayment Reduction Intervention and Persistence and Adherence to Secondary Prevention Medications Among Patients Who Had Ever and Never Filled an Additional Cardiac Medication Prescription on the Same Day as a P2Y₁₂ Inhibitor Prescription.

There was no interaction observed between whether a patient had ever filled a non–P2Y₁₂ inhibitor secondary prevention medication at the same time as a P2Y₁₂ inhibitor and the observed association with persistence (A) or adherence (B) in taking other cardiovascular medications. Variables for adjustment included hospital characteristics, demographic information, comorbidities, details of the index presentation and hospital course, and patient responses to baseline survey questions about quality of life and medication-taking behaviors. ACE indicates antiotengin-converting enzyme; ARB, angiotension II–receptor blocker.